交易中 11-18 10:57:17 美东时间
-0.070
-5.60%
Nkarta (NKTX) reports positive Phase 1/2 safety data for NKX019 cell therapy with zero severe immune toxicities across 5 autoimmune diseases.
11-11 23:44
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period last year.
05-13 04:33
NKGen Biotech has activated two new clinical trial sites, the Ottawa Memory Clinic in Canada and AdventHealth Orlando in the U.S., to expand access and accelerate recruitment for its Phase 1/2a trial of troculeucel for moderate Alzheimer’s disease.
2025-06-23 12:05
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $23 to $22.
2024-08-15 18:05